Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy|Continue
Sign In
Individual Sign In
Access through your institution
Purchase Options:
Top of Article
- Key Points
- Abstract
- Introduction
- Methods
- Results
- Discussion
- Conclusions
- Article Information
- References
Figure. Studies on the Association of Opioid Agonist Treatment (OAT) With All-Cause Mortality From Cohort Studies by Administration of Buprenorphine or Methadone
Weights are from random-effects analysis.
Table 1. Findings From Observational Studies on the Association of Time During Opioid Agonist Treatment (OAT) and Out of OAT With All-Cause Mortality According to Demographic, Clinical, and Study-Level Variables
Table 2. Findings From Observational Studies on the Pooled All-Cause and Cause-Specific Crude Mortality Rates, and Mortality Rate Ratios Among People With Opioid Dependence According to Time Spent During and Out of OAT
Table 3. Findings From Observational Studies on the Pooled Cause-Specific Rates Among People Receiving OAT, by Time During Incarceration and After Release From Incarceration
Table 4. Summary of Studies That Adjusted for Confounding in Observational Studies of the Association of OAT With Mortality
Irvine MA, Kuo M, Buxton JA, et al. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. Addiction. 2019;114(9):1602-1613. doi:10.1111/add.14664PubMedGoogle ScholarCrossref
Degenhardt L, Grebely J, Stone J, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560-1579. doi:10.1016/S0140-6736(19)32229-9 PubMedGoogle ScholarCrossref
Wen LS, Sadeghi NB. The opioid crisis and the 2020 US election: crossroads for a national epidemic. Lancet. 2020;396(10259):1316-1318. doi:10.1016/S0140-6736(20)32113-9 PubMedGoogle ScholarCrossref
Brignone E, George DR, Sinoway L, et al. Trends in the diagnosis of diseases of despair in the United States, 2009-2018: a retrospective cohort study. BMJ Open. 2020;10(10):e037679. doi:10.1136/bmjopen-2020-037679 PubMedGoogle ScholarCrossref
Larney S, Tran LT, Leung J, et al. All-cause and cause-specific mortality among people using extramedical opioids: a systematic review and meta-analysis. JAMA Psychiatry. 2020;77(5):493-502. doi:10.1001/jamapsychiatry.2019.4170 PubMedGoogle ScholarCrossref
World Health Organization. WHO Model list of essential medicines. Accessed February 15, 2020. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists
Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:10.1136/bmj.j1550 PubMedGoogle ScholarCrossref
Stevens GA, Alkema L, Black RE, et al; GATHER Working Group. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet. 2016;388(10062):e19-e23. doi:10.1016/S0140-6736(16)30388-9 PubMedGoogle ScholarCrossref
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269, W64. doi:10.7326/0003-4819-151-4-200908180-00135 PubMedGoogle ScholarCrossref
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008 PubMedGoogle ScholarCrossref
Examining the effect of opioid agonist treatment on all-cause and cause-specific mortality. PROSPERO identifier: CRD42020171949. Updated April 28, 2020. Accessed April 21, 2021. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=171949
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919-i. doi:10.1136/bmj.i4919 PubMedGoogle ScholarCrossref
Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:I4898. doi:10.1136/bmj.l4898PubMed
Randall D, Roxburgh A, Gibson A, Degenhardt L. Mortality among people who use illicit drugs: a toolkit for classifying major causes of death. Accessed January 23, 2010. https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/Randall%20et%20al%20Classifying%20causes%20of%20death%202009%20corrected.pdf
StataCorp. Stata Statistical Software: Release 16. StataCorp, LLC; 2019.
Harris RJ, Deeks JJ, Altman DG, Bradburn MJ, Harbord RM, Sterne JA. Metan: fixed-and random-effects meta-analysis. SJ. 2008;8(1):3-28.
Harbord R, Higgins J. Metareg: Stata Module to Perform Meta-Analysis Regression. Boston College Department of Economics; 2009.
Larney S, Gisev N, Farrell M, et al. Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. BMJ Open. 2014;4(4):e004666. doi:10.1136/bmjopen-2013-004666 PubMedGoogle ScholarCrossref
Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O'Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33-40. doi:10.1016/j.drugalcdep.2014.05.011PubMedGoogle ScholarCrossref
Gruber VA, Delucchi KL, Kielstein A, Batki SL. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 2008;94(1-3):199-206. doi:10.1016/j.drugalcdep.2007.11.021PubMedGoogle ScholarCrossref
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O'Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat. 2009;37(3):277-285. doi:10.1016/j.jsat.2009.03.002PubMedGoogle ScholarCrossref
Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309-318. doi:10.1016/S0140-6736(17)32812-XPubMedGoogle ScholarCrossref
Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA. 2010;304(14):1576-1583. doi:10.1001/jama.2010.1427PubMedGoogle ScholarCrossref
Rich JD, McKenzie M, Larney S, et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015;386(9991):350-359. doi:10.1016/S0140-6736(14)62338-2PubMedCrossref
Strain E, Stitzer M, Liebson I, Bigelow G. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993;119(1):23-27. doi:10.7326/0003-4819-119-1-199307010-00004PubMedCrossref
Yancovitz SR, Des Jarlais DC, Peyser NP, et al. A randomized trial of an interim methadone maintenance clinic. Am J Public Health. 1991;81(9):1185-1191. doi:10.2105/ajph.81.9.1185PubMedCrossref
Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662-668. doi:10.1016/S0140-6736(03)12600-1PubMedCrossref
Krook AL, Brors O, Dahlberg J, et al. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction. 2002;97(5):533-542. doi:10.1046/j.1360-0443.2002.00090.xPubMedCrossref
Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9631):2192-2200. doi:10.1016/S0140-6736(08)60954-XPubMedCrossref
Tanum L, Solli KK, Latif ZE, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74(12):1197-1205. doi:10.1001/jamapsychiatry.2017.3206PubMedCrossref
Newman R, Whitehill W. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2(8141):485-488. doi:10.1016/s0140-6736(79)91550-2PubMedCrossref
Gunne LM, Grönbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend. 1981;7(3):249-256. doi:10.1016/0376-8716(81)90096-xPubMedCrossref
Metzger DS, Donnell D, Celentano DD, et al. Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058. J Acquir Immune Defic Syndr. 2015;68(5):554-561. doi:10.1097/QAI.0000000000000510PubMedCrossref
Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment—a nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58-64. doi:10.1016/j.drugalcdep.2017.01.013 PubMedGoogle ScholarCrossref
Bakker A, Streel E. Benzodiazepine maintenance in opiate substitution treatment: good or bad? a retrospective primary care case-note review. J Psychopharmacol. 2017;31(1):62-66. doi:10.1177/0269881116675508 PubMedGoogle ScholarCrossref
Bukten A, Stavseth MR, Clasuen T. From restrictive to more liberal: variations in mortality among patients in opioid maintenance treatment over a 12-year period. BMC Health Serv Res. 2019;19(1):553. doi:10.1186/s12913-019-4382-9 PubMedGoogle ScholarCrossref
Buster MC, van Brussel GH, van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction. 2002;97(8):993-1001. doi:10.1046/j.1360-0443.2002.00179.x PubMedGoogle ScholarCrossref
Cousins G, Teljeur C, Motterlini N, McCowan C, Dimitrov BD, Fahey T. Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study. J Subst Abuse Treat. 2011;41(3):252-260. doi:10.1016/j.jsat.2011.05.001 PubMedGoogle ScholarCrossref
Cousins G, Boland F, Courtney B, Barry J, Lyons S, Fahey T. Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study. Addiction. 2016;111(1):73-82. doi:10.1111/add.13087 PubMedGoogle ScholarCrossref
Davoli M, Bargagli AM, Perucci CA, et al; VEdeTTE Study Group. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction. 2007;102(12):1954-1959. doi:10.1111/j.1360-0443.2007.02025.x PubMedGoogle ScholarCrossref
Dupouy J, Palmaro A, Fatséas M, et al. Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-year cohort study. Ann Fam Med. 2017;15(4):355-358. doi:10.1370/afm.2098 PubMedGoogle ScholarCrossref
Durand L, O'Driscoll D, Boland F, et al. Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug-related poisoning deaths? a retrospective-cohort study. Addiction. 2020;115(10):1867-1877. doi:10.1111/add.15004PubMedCrossref
Fugelstad A, Stenbacka M, Leifman A, Nylander M, Thiblin I. Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction. 2007;102(3):406-412. doi:10.1111/j.1360-0443.2006.01714.x PubMedGoogle ScholarCrossref
Grönbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82(3):223-227. doi:10.1111/j.1600-0447.1990.tb03057.x PubMedGoogle ScholarCrossref
Hickman M, Steer C, Tilling K, et al. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. Addiction. 2018;113(8):1461-1476. doi:10.1111/add.14188 PubMedGoogle ScholarCrossref
Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health. 2001;91(5):774-780. doi:10.2105/AJPH.91.5.774 PubMedGoogle ScholarCrossref
Marsden J, Stillwell G, Jones H, et al. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? a national prospective observational study in England. Addiction. 2017;112(8):1408-1418. doi:10.1111/add.13779 PubMedGoogle ScholarCrossref
Morozova O, Dvoryak S, Altice FL. Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine. Int J Drug Policy. 2013;24(6):e91-e98. doi:10.1016/j.drugpo.2013.09.001 PubMedGoogle ScholarCrossref
Muga R, Rivas I, Faure E, et al. Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study. BMC Infect Dis. 2014;14:504. doi:10.1186/1471-2334-14-504 PubMedGoogle ScholarCrossref
Pavarin RM, Fioritti A, Sanchini S. Mortality trends among heroin users treated between 1975 and 2013 in Northern Italy: results of a longitudinal study. J Subst Abuse Treat. 2017;77:166-173. doi:10.1016/j.jsat.2017.02.009 PubMedGoogle ScholarCrossref
Pierce M, Bird SM, Hickman M, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction. 2016;111(2):298-308. doi:10.1111/add.13193 PubMedGoogle ScholarCrossref
Scherbaum N, Specka M, Hauptmann G, Gastpar M. Does maintenance treatment reduce the mortality rate of opioid addicts?. Article written in German. Fortschr Neurol Psychiatr. 2002;70(9):455-461. doi:10.1055/s-2002-33758 PubMedGoogle ScholarCrossref
Weber R, Ledergerber B, Opravil M, Siegenthaler W, Lüthy R. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. BMJ. 1990;301(6765):1362-1365. doi:10.1136/bmj.301.6765.1362 PubMedGoogle ScholarCrossref
Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009;105(1-2):9-15. doi:10.1016/j.drugalcdep.2009.05.021 PubMedGoogle ScholarCrossref
Digiusto E, Shakeshaft A, Ritter A, O’Brien S, Mattick RP; NEPOD Research Group. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004;99(4):450-460. doi:10.1111/j.1360-0443.2004.00654.x PubMedGoogle ScholarCrossref
Fellows-Smith J. Opioid-dependent error processing. J Opioid Manag. 2011;7(6):443-449.PubMedGoogle Scholar
Kelty E, Joyce D, Hulse G. A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine. Am J Drug Alcohol Abuse. 2019;45(3):285-291. doi:10.1080/00952990.2018.1545131 PubMedGoogle ScholarCrossref
Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry. 2015;2(10):901-908. doi:10.1016/S2215-0366(15)00366-1 PubMedGoogle ScholarCrossref
Reece AS. Favorable mortality profile of naltrexone implants for opiate addiction. J Addict Dis. 2010;29(1):30-50. doi:10.1080/10550880903435988 PubMedGoogle ScholarCrossref
Bazazi AR. Characterizing and Responding to the Epidemics of HIV and Injection Drug Use in Malaysia. Dissertation. Yale University; 2018.
Chang KC, Lu TH, Lee KY, Hwang JS, Cheng CM, Wang JD. Estimation of life expectancy and the expected years of life lost among heroin users in the era of opioid substitution treatment (OST) in Taiwan. Drug Alcohol Depend. 2015;153:152-158. doi:10.1016/j.drugalcdep.2015.05.033 PubMedGoogle ScholarCrossref
Huang YF, Kuo HS, Lew-Ting CY, et al. Mortality among a cohort of drug users after their release from prison: an evaluation of the effectiveness of a harm reduction program in Taiwan. Addiction. 2011;106(8):1437-1445. doi:10.1111/j.1360-0443.2011.03443.x PubMedGoogle ScholarCrossref
Huang CL, Lee CW. Factors associated with mortality among heroin users after seeking treatment with methadone: a population-based cohort study in Taiwan. J Subst Abuse Treat. 2013;44(3):295-300. doi:10.1016/j.jsat.2012.08.003 PubMedGoogle ScholarCrossref
Liu E, Rou K, McGoogan JM, et al; China’s National Working Group on Methadone Maintenance Treatment. Factors associated with mortality of HIV-positive clients receiving methadone maintenance treatment in China. J Infect Dis. 2013;208(3):442-453. doi:10.1093/infdis/jit163 PubMedGoogle ScholarCrossref
Appel PW, Joseph H, Richman BL. Causes and rates of death among methadone maintenance patients before and after the onset of the HIV/AIDS epidemic. Mt Sinai J Med. 2000;67(5-6):444-451.PubMedGoogle Scholar
Evans E, Li L, Min J, et al. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015;110(6):996-1005. doi:10.1111/add.12863 PubMedGoogle ScholarCrossref
Gearing FR, Schweitzer MD. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. Am J Epidemiol. 1974;100(2):101-112. doi:10.1093/oxfordjournals.aje.a112012 PubMedGoogle ScholarCrossref
Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137-145. doi:10.7326/M17-3107 PubMedGoogle ScholarCrossref
Pearce LA, Min JE, Piske M, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020;368:m772. doi:10.1136/bmj.m772 PubMedGoogle ScholarCrossref
Ledberg A. Mortality related to methadone maintenance treatment in Stockholm, Sweden, during 2006-2013. J Subst Abuse Treat. 2017;74:35-41. doi:10.1016/j.jsat.2016.12.005 PubMedGoogle ScholarCrossref
Degenhardt L, Larney S, Kimber J, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014;109(8):1306-1317. doi:10.1111/add.12536 PubMedGoogle ScholarCrossref
Lawlor DA, Davey Smith G, Ebrahim S. Commentary: the hormone replacement–coronary heart disease conundrum: is this the death of observational epidemiology? Int J Epidemiol. 2004;33(3):464-467. doi:10.1093/ije/dyh124 PubMedGoogle ScholarCrossref
Zhang FF, Barr SI, McNulty H, Li D, Blumberg JB. Health effects of vitamin and mineral supplements. BMJ. 2020;369:m2511. doi:10.1136/bmj.m2511 PubMedGoogle ScholarCrossref
Pintilie M. Competing Risks: A Practical Perspective: John Wiley & Sons; 2006. doi:10.1002/9780470870709
O’Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS One. 2020;15(5):e0232086. doi:10.1371/journal.pone.0232086 PubMedGoogle ScholarCrossref
Nosyk B, MacNab YC, Sun H, et al. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol. 2009;170(6):783-792. doi:10.1093/aje/kwp186 PubMedGoogle ScholarCrossref
Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ. 2010;341:c3172. doi:10.1136/bmj.c3172 PubMedGoogle ScholarCrossref
Gisev N, Shanahan M, Weatherburn DJ, et al. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. Addiction. 2015;110(12):1975-1984. doi:10.1111/add.13073 PubMedGoogle ScholarCrossref
Department of Health. Drug misuse and dependence. Accessed April 15, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/673978/clinical_guidelines_2017.pdf
Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ. 2010;341(7779):c5475. doi:10.1136/bmj.c5475 PubMedGoogle ScholarCrossref
Zhang L, Zou X, Zhang D, Li X, Zhao P, Ling L. Investigation of repeat client drop-out and re-enrolment cycles in fourteen methadone maintenance treatment clinics in Guangdong, China. PLoS One. 2015;10(10):e0139942. doi:10.1371/journal.pone.0139942PubMedCrossref
-
Error in Abstract
JAMA Psychiatry
Correction
September 1, 2021
-
Error in Abstract
JAMA Psychiatry
Correction
May 1, 2022
-
Errors in Data Reported in Meta-Analysis on Opioid Agonist Treatment and Mortality
JAMA Psychiatry
Comment & Response
September 1, 2023
ThomasSantoJr,MPH, PhD
-
Errors in Results and Tables
JAMA Psychiatry
Correction
September 1, 2023
See More About
Select Your Interests
Select Your Interests
Customize your JAMA Network experience by selecting one or more topics from the list below.
- Academic Medicine
- Acid Base, Electrolytes, Fluids
- Allergy and Clinical Immunology
- American Indian or Alaska Natives
- Anesthesiology
- Anticoagulation
- Art and Images in Psychiatry
- Artificial Intelligence
- Assisted Reproduction
- Bleeding and Transfusion
- Cardiology
- Caring for the Critically Ill Patient
- Challenges in Clinical Electrocardiography
- Climate and Health
- Climate Change
- Clinical Challenge
- Clinical Decision Support
- Clinical Implications of Basic Neuroscience
- Clinical Pharmacy and Pharmacology
- Complementary and Alternative Medicine
- Consensus Statements
- Coronavirus (COVID-19)
- Critical Care Medicine
- Cultural Competency
- Dental Medicine
- Dermatology
- Diabetes and Endocrinology
- Diagnostic Test Interpretation
- Drug Development
- Electronic Health Records
- Emergency Medicine
- End of Life, Hospice, Palliative Care
- Environmental Health
- Equity, Diversity, and Inclusion
- Ethics
- Facial Plastic Surgery
- Gastroenterology and Hepatology
- Genetics and Genomics
- Genomics and Precision Health
- Geriatrics
- Global Health
- Guide to Statistics and Methods
- Guidelines
- Hair Disorders
- Health Care Delivery Models
- Health Care Economics, Insurance, Payment
- Health Care Quality
- Health Care Reform
- Health Care Safety
- Health Care Workforce
- Health Disparities
- Health Inequities
- Health Policy
- Health Systems Science
- Hematology
- History of Medicine
- Humanities
- Hypertension
- Images in Neurology
- Implementation Science
- Infectious Diseases
- Innovations in Health Care Delivery
- JAMA Infographic
- Law and Medicine
- Leading Change
- Less is More
- LGBTQIA Medicine
- Lifestyle Behaviors
- Medical Coding
- Medical Devices and Equipment
- Medical Education
- Medical Education and Training
- Medical Journals and Publishing
- Melanoma
- Mobile Health and Telemedicine
- Narrative Medicine
- Nephrology
- Neurology
- Neuroscience and Psychiatry
- Notable Notes
- Nursing
- Nutrition
- Nutrition, Obesity, Exercise
- Obesity
- Obstetrics and Gynecology
- Occupational Health
- Oncology
- Ophthalmology
- Orthopedics
- Otolaryngology
- Pain Medicine
- Palliative Care
- Pathology and Laboratory Medicine
- Patient Care
- Patient Information
- Pediatrics
- Performance Improvement
- Performance Measures
- Perioperative Care and Consultation
- Pharmacoeconomics
- Pharmacoepidemiology
- Pharmacogenetics
- Pharmacy and Clinical Pharmacology
- Physical Medicine and Rehabilitation
- Physical Therapy
- Physician Leadership
- Poetry
- Population Health
- Primary Care
- Professional Well-being
- Professionalism
- Psychiatry and Behavioral Health
- Public Health
- Pulmonary Medicine
- Radiology
- Regulatory Agencies
- Reproductive Health
- Research, Methods, Statistics
- Resuscitation
- Rheumatology
- Risk Management
- Scientific Discovery and the Future of Medicine
- Shared Decision Making and Communication
- Sleep Medicine
- Sports Medicine
- Stem Cell Transplantation
- Substance Use and Addiction Medicine
- Surgery
- Surgical Innovation
- Surgical Pearls
- Teachable Moment
- Technology and Finance
- The Art of JAMA
- The Arts and Medicine
- The Rational Clinical Examination
- Tobacco and e-Cigarettes
- Toxicology
- Translational Medicine
- Trauma and Injury
- Treatment Adherence
- Ultrasonography
- Urology
- Users' Guide to the Medical Literature
- Vaccination
- Venous Thromboembolism
- Veterans Health
- Violence
- Women's Health
- Workflow and Process
- Wound Care, Infection, Healing
Save Preferences
Others Also Liked
Comment
- Download PDF
-
Citation
Santo T, Clark B, Hickman M, et al. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;78(9):979–993. doi:10.1001/jamapsychiatry.2021.0976
Manage citations:
© 2024
Original Investigation
June 2, 2021
ThomasSantoJr,MPH1; BrodieClark,BPsych1; MattHickman,PhD2; et al JasonGrebely,PhD3; GabrielleCampbell,PhD1,4; LuisSordo,MD, PhD5,6; AileenChen,BPsych1,7; Lucy ThiTran,BPsychSc1; ChriannaBharat,BSc1; PriankaPadmanathan,MRCPsych2; GrainneCousins,PhD8; JulieDupouy,MD, PhD9,10; ErinKelty,PhD11; RobertoMuga,MD, PhD12; BohdanNosyk,PhD13,14; JeongMin,MSc13; RaimondoPavarin,MPH15,16; MichaelFarrell,MD1; LouisaDegenhardt,PhD1
Author Affiliations Article Information
-
1National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Sydney, Australia
-
2Population Health Sciences, University of Bristol, Bristol, United Kingdom
-
3Kirby Institute, University of New South Wales, Sydney, Sydney, Australia
-
4University of the Sunshine Coast, Sunshine Coast, Queensland, Australia
-
5Consortium for Biomedical Research in Epidemiology and Public Health, Madrid, Spain
-
6Department of Preventive Medicine and Public Health, Faculty of Medicine, Complutense University, Madrid, Spain
-
7Clinical Research Unit for Anxiety and Depression, St Vincent's Hospital, Sydney, New South Wales, Australia
-
8School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland
-
9University Department of General Medicine, University of Toulouse, Faculty of Medicine, Toulouse, France
-
10Inserm UMR1027, University of Toulouse III, Faculty of Medicine, Toulouse, France
-
11The School of Population & Global Health, The University of Western Australia, Perth, Australia
-
12Department of Internal Medicine, Germans Trias i Pujol-IGTP University Hospital, Autonomous University of Barcelona, Barcelona, Spain
-
13British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada
-
14Faculty of Health Sciences, Simon Fraser University, Vancouver, British Columbia, Canada
-
15Epidemiological Monitoring Center on Addiction, Azienda Unità Sanitaria Locale Bologna, Mental Health Dipartimento Salute Mentale – Dipendenze Patologiche, Bologna, Italy
-
16Italian Society on Addiction, Milan, Italy
JAMA Psychiatry. 2021;78(9):979-993. doi:10.1001/jamapsychiatry.2021.0976
-
Correction
Error in Abstract
JAMA Psychiatry
-
Correction
Error in Abstract
JAMA Psychiatry
-
Comment & Response
Errors in Data Reported in Meta-Analysis on Opioid Agonist Treatment and Mortality
ThomasSantoJr,MPH, PhD
JAMA Psychiatry
-
Correction
Errors in Results and Tables
JAMA Psychiatry
Question Is opioid agonist treatment (OAT) associated with risk of overall and cause-specific mortality among people with opioid dependence?
Findings In this systematic review and meta-analysis, risk of all-cause, overdose, suicide, alcohol-related, cancer, and cardiovascular-related mortality was significantly lower for people with opioid dependence during OAT.
Meaning These findings suggest that increasing access to OAT and retention in treatment are critical for reducing rates of preventable mortality among people with opioid dependence.
Abstract
Importance Mortality among people with opioid dependence is higher than that of the general population. Opioid agonist treatment (OAT) is an effective treatment for opioid dependence; however, there has not yet been a systematic review on the relationship between OAT and specific causes of mortality.
Objective To estimate the association of time receiving OAT with mortality.
Data Sources The Embase, MEDLINE, and PsycINFO databases were searched through February 18, 2020, including clinical trial registries and previous Cochrane reviews.
Study Selection All observational studies that collected data on all-cause or cause-specific mortality among people with opioid dependence while receiving and not receiving OAT were included. Randomized clinical trials (RCTs) were also included.
Data Extraction and Synthesis This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Data on study, participant, and treatment characteristics were extracted; person-years, all-cause mortality, and cause-specific mortality were calculated. Crude mortality rates and rate ratios (RRs) were pooled using random-effects meta-analyses.
Main Outcomes and Measures Overall all-cause and cause-specific mortality both by setting and by participant characteristics. Methadone and buprenorphine OAT were evaluated specifically.
Results Fifteen RCTs including 3852 participants and 36 primary cohort studies including 749 634 participants were analyzed. Among the cohort studies, the rate of all-cause mortality during OAT was more than half of the rate seen during time out of OAT (RR, 0.47; 95% CI, 0.42-0.53). This association was consistent regardless of patient sex, age, geographic location, HIV status, and hepatitis C virus status and whether drugs were taken through injection. Associations were not different for methadone (RR, 0.47; 95% CI, 0.41-0.54) vs buprenorphine (RR, 0.34; 95% CI, 0.26-0.45). There was lower risk of suicide (RR, 0.48; 95% CI, 0.37-0.61), cancer (RR, 0.72; 95% CI, 0.54-0.98), drug-related (RR, 0.41; 95% CI, 0.33-0.52), alcohol-related (RR, 0.59; 95% CI, 0.49-0.72), and cardiovascular-related (RR, 0.69; 95% CI, 0.60-0.79) mortality during OAT. In the first 4 weeks of methadone treatment, rates of all-cause mortality and drug-related poisoning were more than double the rates during the remainder of OAT (RR, 2.81; 95% CI, 1.55-5.09) but not for buprenorphine (RR, 0.58; 95% CI, 0.18-1.85). All-cause mortality was 6 times higher in the 4 weeks after OAT cessation (RR, 6.01; 95% CI, 4.32-8.36), remaining double the rate for the remainder of time not receiving OAT (RR, 1.81; 95% CI, 1.50-2.18). Opioid agonist treatment was associated with a lower risk of mortality during incarceration (RR, 0.06; 95% CI, 0.01-0.46) and after release from incarceration (RR, 0.09; 95% CI, 0.02-0.56).
Conclusions and Relevance This systematic review and meta-analysis found that OAT was associated with lower rates of mortality. However, access to OAT remains limited, and coverage of OAT remains low. Work to improve access globally may have important population-level benefits.
Introduction
Opioid dependence is increasing in many countries, particularly in North America, where there have been substantial increases in opioid-related health harms, specifically overdose.1,2 In the US during the COVID-19 pandemic, opioid overdoses have increased in some states by up to 30% in 2020 compared with those in 2019.3 Population-level increases in “deaths of despair,” including suicides, injuries, and liver disease, have also been observed.4 People with opioid dependence are at an elevated risk of a range of causes of death beyond deaths of despair, including other acute and systemic causes such as unintentional opioid and suicide-related death, and all liver-related, alcohol-related, cancer-related, chronic respiratory–related, digestive-related, HIV-related, influenza- and pneumonia-related, and injection-related injuries.2,5
Methadone and buprenorphine are classified by the World Health Organization as essential medicines for opioid agonist treatment (OAT) for opioid dependence.6 There is robust evidence from a recent systematic review that during OAT, overdose and all-cause mortality are reduced among people with opioid dependence.7 That review also found that people who cease OAT are at the highest risk of all-cause and overdose mortality in the first 4 weeks after treatment cessation7 and that risk of mortality is elevated in the first 4 weeks of OAT compared with the remainder of time receiving OAT.7
To our knowledge, there has not been a systematic examination of (1) the evidence on the potential association of OAT with other causes of death or (2) OAT provided in alternative settings, including during and immediately after incarceration. In this review, we aim to (1) examine and compare all-cause and cause-specific crude mortality rates (CMRs) during and out of OAT, for both randomized clinical trials (RCTs) and observational studies; (2) examine these rates according to specific periods during and after treatment; (3) examine and compare all-cause and cause-specific CMRs for OAT provided during incarceration, after release from incarceration while receiving OAT, and according to the amount of time receiving and not receiving OAT after release from incarceration; and (4) examine the association between risk of mortality during and out of OAT by participant and treatment characteristics.
Methods
This systematic review and meta-analysis was conducted from January 15 to February 18, 2020. As this was a review, this study was not approved by an institutional review board. We reported on published, peer-reviewed data. Each included study obtained approval from their respective jurisdictions. This study followed the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER),8 Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline,9 and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guideline.10 The protocol was registered on PROSPERO.11
Search Strategy and Inclusion Criteria
We systematically searched 3 peer-reviewed databases (Medline, Embase, and PsycINFO) without language limitation; database searches were completed on February 18, 2020. Search terms included exploded MeSH terms and keywords for opioid dependence, OAT, and mortality (eAppendix in the Supplement). We consulted experts and investigators with ongoing studies of mortality among people with opioid dependence, authors of studies included in a previous review7 of OAT and mortality, systematic reviews of OAT and opioid dependence, and clinical registries.
Eligible studies had to report mortality data for people with opioid dependence during and out of OAT (prespecified exclusion criteria and excluded studies are in the eAppendix and eTable 1 in the Supplement). We included both observational studies and RCTs. Observational studies that reported any form of mortality and person-time data for time during OAT and out of OAT were included. Randomized clinical trials were required to report mortality data for participants allocated to OAT and those allocated to control or comparator interventions separately. Authors of studies that did not report mortality or person-time data during and after OAT separately were contacted for additional information.
Study Selection and Data Extraction
Two reviewers independently reviewed the titles and abstracts identified in the search and retrieved articles to determine eligibility; full texts were also independently reviewed (T.S., B.C., L.T.T.). Conflicts were resolved by consensus with a third reviewer (L.D., J.G., G.C.). If additional data were required for the primary analyses in any setting or the secondary analyses (eg, medication type, time spent in or out of treatment, and participant characteristics), then the study authors were contacted.
We extracted information on participant and study characteristics, treatment modality characteristics, number of deaths, person-years at risk, and all-cause and cause-specific mortality rates during follow-up periods during and after treatment cessation (eTables 2, 3, and 4 in the Supplement). All extracted data were confirmed by a second person (T.S., B.C., or L.T.T.).
We assessed risk of bias using the Risk Of Bias In Nonrandomized Studies–of Interventions (ROBINS-I) tool for observational studies12; and Risk of Bias 2 (RoB-2)13 tool for RCTs. Two reviewers (T.S., B.C., or L.T.T.) assessed each study independently with conflicts resolved by a third party (L.D., J.G., or G.C.).
Classifying Causes of Mortality
We reported on multiple causes of death using the primary cause of death assigned to each fatality. To standardize the definitions for cause-specific deaths included in each study, we contacted study authors asking them to provide data using specified International Classification of Diseases, Ninth Revision (ICD-9) and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)14 codes (eTable 5 in the Supplement).
Statistical Analysis
For RCTs, log-transformed rate ratios (RRs) were calculated by comparing binary death and participant totals using the Mantel-Haenszel fixed method. For observational cohorts, observed number of deaths were divided by person-years (PYs) to calculate crude mortality rates (CMRs) for all and specific causes during periods in and out of treatment. Unadjusted log-transformed RRs for each study were calculated by comparing CMRs for time during and out of treatment. Crude mortality rates for each period and RRs were pooled using random-effects meta-analyses with exact 95% CIs assuming a Poisson distribution. Heterogeneity was quantified using the I2 statistic. Analyses were conducted in Stata, version 16.1,15 using the metan16 command for meta-analyses and the metareg17 command for meta-regressions (StataCorp). Significance was set at P < .05, and all P values were 2-sided.
Separate analyses of mortality risk were conducted for studies of patients who were incarcerated, observational studies of people released from prison with or without OAT, and studies that monitored time in or out of OAT after release from prison. Pooled analyses were conducted for all-cause and cause-specific mortality for the first 4 weeks during OAT and after OAT cessation and the remainder of time during and out of OAT. Crude mortality rates were calculated for each of the 4 periods, and RRs were calculated with the remainder of time in treatment as the reference period. We performed sensitivity analyses by excluding studies with participants who had no record of OAT during the study, studies at high risk of bias owing to missing data or loss to follow-up, and any studies of participants who were positive for HIV and released from prison.
Results
Of the 7980 studies identified, 72 publications fulfilled inclusion criteria (eFigure 1 in the Supplement; a list of articles excluded during full-text review is in eTable 1 in the Supplement). A total of 15 RCTs including 3852 participants and 36 primary cohort studies including 749 634 participants were eligible for analysis. An additional 21 articles were not included analyses despite fulfilling the inclusion criteria due to participant overlap: 3 were included in subanalyses (C. Bharat, personal communication, 2021; eTable 6 in the Supplement for secondary publications).15,18
Randomized Clinical Trials
Characteristics of Included Studies
Characteristics of RCTs are presented in eTables 4 and 6 to 13 in the Supplement. Eight of 15 RCTs (53%)19-26 were conducted in North America and at single clinics (8 [53%]19-26). Buprenorphine was studied in 7 of 15 of the RCTs (47%),19,22,23,27-30 and the most common comparator was detoxification alone (5 [33%]20,25,27,29,31). Most RCTs (12 of 15 [80%]19-22,25-29,31-33) commenced before 2010 and lasted 6 months or less (9 [60%]19,20,23-26,28-30). Eight of the RCTs (53%)19,20,23,26,27,29-31 had greater than 20% of participants lost to follow-up.
All-Cause Mortality During and Out of OAT
In total, 45 deaths were reported across RCTs; 7 of 15 RCTs (47%) reported 0 deaths.19,20,23,25,28-30 There was no significant difference in all-cause mortality for patients allocated to OAT compared with comparison groups (RR, 0.86; 95% CI, 0.59-1.23) (eFigure 2 in the Supplement). Three of 15 RCTs (20%) evaluated the administration of OAT to patients who were incarcerated; no deaths were reported (eFigure 2 in the Supplement).19,21,24
Observational Studies
Characteristics of Included Studies
Characteristics of observational studies are presented in eTables 4 and 6 to13 in the Supplement. Cohorts ranged from 110 to 306 786 participants and included people from Europe (20 of 36 studies [58%]34-53; 278 977 people), Australia (6 studies [17%]54-59; 103 715 people), Asia (5 studies60-64 [14%]; 311 658 people), and North America (5 studies65-69 [14%]; 110 631 people). Seventeen studies (47%)34,35,39,41,42,45,47-50,57,58,61,64,66,68,69 concluded follow-up in 2010 or later. Sixteen studies (44%)34,36-39,41,42,45,50,51,54,57,58,66,68,69 used OAT registry data. Mortality data during and after OAT were stratified by methadone treatment for 28 of 36 studies (78%)37-40,42-46,48,49,52-58,60-67,69,70 and by buprenorphine treatment for 8 of 36 studies (22%).41,45,54,55,57-59,69 Type of OAT was unspecified in 6 of 36 studies (17%).35,36,47,50,51,68
All-Cause Mortality During and Out of OAT
The pooled all-cause CMR while enrolled in any form of OAT was 11.00 deaths per 1000 PY (95% CI, 9.20-13.16) compared with 23.97 deaths per 1000 PY when not receiving OAT (95% CI, 19.92-28.83). Being in OAT was associated with more than half the risk of mortality (RR, 0.47; 95% CI, 0.42-0.53; 30 of 36 studies [83%]34-36,38,39,41-45,48-50,52-59,61-69; 562 714 patients) (eFigure 3 in the Supplement). The association was not different for methadone (RR, 0.47; 95% CI, 0.41-0.54; 23 of 36 studies [64%]38-40,42-46,48,49,52-54,56,57,61-67,69) or buprenorphine (RR, 0.34; 95% CI, 0.26-0.45; 8 of 36 studies [22%]41,45,54,55,57-59,69) (Figure).
Table 1 shows mortality rates and RRs for time in and out of OAT according to participant characteristics, treatment administrators, study methodologies, and region. Although absolute mortality rates during and after OAT varied (Table 1), the RRs for time during and out of OAT were similar across subgroups of people with opioid dependence (eg, by sex, age group, HIV or hepatitis C virus [HCV] status, and taking drugs via injection). Study findings were consistent across study design, mortality ascertainment method, and region. Meta-regressions found no evidence for variation of RR by study year, sample size, follow-up time, age, proportion of women, proportion of people who inject drugs, or people with HIV or HCV (Table 1; eTable 14 in the Supplement).
Cause-Specific Mortality During and Out of OAT
Results of all-cause and cause-specific mortality analyses are presented in Table 2. While receiving OAT, people with opioid dependence were at lower risk of all injury and poisoning (pooled RR, 0.34; 95% CI, 0.27-0.42), suicide (pooled RR, 0.48; 95% CI, 0.37-0.61), cancer (pooled RR, 0.72; 95% CI, 0.54-0.98), and alcohol-related (pooled RR, 0.59; 95% CI, 0.49-0.72) and cardiovascular-related (pooled RR, 0.69; 95% CI, 0.60-0.79) mortality. The strongest association with lower mortality risk while receiving OAT was observed for deaths related to injury or poisoning, specifically, unintentional drug-related death (pooled RR, 0.41; 95% CI, 0.33-0.52) and suicide (pooled RR, 0.48; 95% CI, 0.37-0.61). Liver disease–related deaths in general were lower during OAT, but there was an association between OAT and viral hepatitis mortality (RR, 1.35; 95% CI, 1.15-1.60). Forest plots for each cause of death are presented in eFigures 4-24 in the Supplement.
Mortality by Specific Periods During OAT and After OAT Cessation
Stratified OAT time interval and all-cause mortality data were available for 1438,39,41,42,45,49,50,54,58,61,62,65,69,70 cohort studies (39%; 175 213 people). The remainder of time spent in OAT (after the first 4 weeks of treatment) was the period of lowest mortality risk overall. In the first 4 weeks of OAT, all-cause mortality was almost double that in the remainder of time spent in treatment (RR, 1.92; 95% CI, 1.10-3.35). Compared with the remainder of time spent in OAT, all-cause mortality was 6 times higher in the first 4 weeks after OAT cessation (RR, 6.01; 95% CI, 4.32-8.36) and remained at double the rate for the remainder of time spent while not receiving OAT (RR, 1.81; 95% CI, 1.50-2.18) (Figure; eFigure 26 in the Supplement). A similar pattern emerged for drug-induced and unintentional opioid-related deaths.
Acute causes of mortality that may be associated with OAT are listed in eTable 15 and eFigure 25 in the Supplement; these causes were stratified by times in and out of OAT (forest plots are presented in eFigures 27-33 in the Supplement; data on other causes of death stratified by OAT time period are presented in eTable 16 in the Supplement; and analyses using first 2-week time periods are presented in eTable 17 in the Supplement). Cause-specific mortality rates were lowest after the first 4 weeks in OAT (ie, remainder in OAT; eTable 15 in the Supplement). For pooled RRs, rate of mortality during the remainder of time receiving OAT was used as the referent. Because of insufficient mortality data (eg, more than half the included studies reported 0 deaths for a specific cause), RRs were not reported for less common causes of death.
Mortality During and After Incarceration for People Receiving OAT
Table 3 presents results of analyses during and after incarceration for people receiving OAT compared to those not receiving OAT. Only 1 study18 that examined the OAT during incarceration was identified, with OAT associated with reduced all-cause (RR, 0.06; 95% CI, 0.01-0.46), drug-related, and suicide-related (RR, 0.10; 95% CI, 0.01-0.75) mortality during the first 4 weeks of treatment and the entire time spent in incarceration.
Three studies47,60,71 reported mortality after release from prison for people who initiated OAT during incarceration, compared with those who had opioid dependence and were incarcerated but had not received OAT. All-cause (RR, 0.24; 95% CI, 0.15-0.37) and drug-related (RR, 0.19; 95% CI, 0.10-0.37) mortality was lower during the first 4 weeks after release from prison for people who left incarceration still receiving OAT compared with those who were released but were not receiving OAT.
Two studies62,71 followed all-cause mortality rates while receiving and not receiving OAT after release from incarceration. Time spent in OAT after release was associated with lower all-cause (RR, 0.09; 95% CI, 0.09-0.56) and drug-related mortality (RR, 0.18; 95% CI, 0.10-0.31) in 1 study71 (eFigures 34-36 and eTable 18 in the Supplement).
Study Quality and Risk of Bias
Twelve RCTs (80%) were assessed as having high risk of bias largely due to missing outcome data and measurement of outcome (eFigures 44 and 45 in the Supplement).20,22,23,25-33 Assessments of observational studies using the ROBINS-I tool included in all-cause mortality analyses found that most studies were at moderate risk of bias (26 of 30 [87%]).34-45,49,51,54,56-59,61,63,66-70 Some studies were at serious risk of bias (4 [13%]),50,55,64,65 and 1 study (3%) was at critical risk of bias owing to measurement of mortality data and participant loss to follow-up (eFigures 37 and 38 in the Supplement).48 The sole study of OAT for patients who were incarcerated was at low risk of bias (eFigure 39 in the Supplement).18 The other studies with follow-up time during or out of OAT after incarceration were at moderate risk of bias (eFigures 40-43 in the Supplement).47,60,62,71
Nineteen observational studies conducted multivariable analyses adjusting for a range of potential confounders on all-cause (and in some cases overdose-related) mortality (Table 4).18,34,38-42,45,47,51,54,60,62-64,66,68-70 There was minimal change in the RRs after controlling for confounding, regardless of the variables included (eTable 19 in the Supplement).
Sensitivity analyses are reported in eFigures 46-49 in the Supplement. None of the analyses yielded results that changed the direction or size of associations reported in the main findings.
Discussion
To our knowledge, this systematic review and meta-analysis is the first to document the association of OAT across different settings with both all-cause and cause-specific mortality. We synthesized 36 observational cohort studies that assessed mortality risk during and out of OAT, which represented a 3-fold increase from a previous review of all-cause mortality7 that included 19 cohorts. Our findings suggest a potential public health benefit of OAT, which was associated with a greater than 50% lower risk of all-cause mortality, drug-related deaths, and suicide and was associated with significantly lower rates of mortality for other causes. The association was consistent across a range of participant and study characteristics.
Our results suggest that RCTs of OAT were underpowered to examine mortality risk. There was no significant association between OAT and mortality risk in the pooled community RCTs; in 7 studies,19,20,23,25,28-30 no deaths were reported. None of the 3 RCTs conducted on the effect of OAT during or after incarceration could be used to guide inferences.19,21,24
Several examples of discrepant findings and conclusions on the benefits of treatment between RCTs and observational studies, such as hormone replacement treatment on cardiovascular outcomes72 and vitamin, mineral, or fish oil supplements on noncommunicable disease,73 exist. Discrepancies between findings from RCTs and observational studies and mortality outcomes described in the current review are not the same because (1) associations between OAT and all-cause mortality (as well as overdose and suicide) were strong, and (2) there was little difference between adjusted and unadjusted estimates; therefore, it was unlikely that unmeasured confounding would alter the findings.
People with opioid dependence were at substantially lower risk of suicide, cancer, drug-related, alcohol-related, and cardiovascular-related mortality during OAT compared with time while not receiving OAT. The association between OAT and a lower risk of overdose was identified in previous reviews.7 The reductions in alcohol-related, cardiovascular-related, and cancer-related mortality may be due to reductions in alcohol use during OAT; similarly, reduced stimulant use may be associated with reduced cardiovascular mortality. The reductions in cardiovascular and cancer-related mortality may also reflect greater access to screening, early intervention, and treatment as a result of improved engagement with treatment administrators.
By contrast, viral hepatitis mortality was higher among those who received OAT. This may reflect an issue of competing risks74 (with people retained in OAT living longer and therefore at higher risk of HCV infection). However, we believe this may have been due to misclassification. As we show in eFigure 49 in the Supplement, 8 cohorts45,49,50,54,57,58,69,70 reported both overall liver-related and viral hepatitis mortality during and out of OAT. There was an elevated risk of mortality due to viral hepatitis, suggesting that OAT status may have affected coronial decisions around attribution of the liver-related cause of death. Until very recently, there were no highly effective treatments for HCV, and coverage availability of HCV treatment has been historically low. There may be an opportunity to further reduce mortality through increasing coverage of HCV treatment as 1 strategy to reduce viral hepatitis mortality in this population.
Despite a hypothesized relationship between OAT and mortality risk due to injection-related injuries and diseases, such as bacterial infections, no such relationship was identified. This may reflect the way in which we operationalized exposure to OAT as overall exposure and according to specific periods of time, but not specifically measured as long-term and stable retention in OAT. The potential for OAT to have an influence on more chronic consequences of dependent opioid use would not be expected except insofar as OAT was being delivered at a certain level of quality and intensity. Although we extracted information on the context of OAT provision where reported, there was often very limited information on the manner of OAT delivery and the other services available to, and received by, people in the cohorts. It is likely that additional interventions will be required to reduce risk of mortality due to injection-related injuries and diseases.
There is a need for more detailed investigation and intervention development to minimize mortality risk during induction of OAT and to maintain patients on OAT who are in critical need of such therapy. A clinical decision support system, stratifying clients’ risk of dropout in real time, may facilitate the identification of those in need of service enhancements to increase engagement and prevent dropout. This will be challenging given limited evidence to support the influence of a number of factors on retention, including age, substance use, OAT dose, legal issues, and attitudes toward OAT.75 There is evidence that people with multiple treatment episodes continue receiving OAT for progressively longer periods in later treatment episodes.39,76 Findings from a Scottish cohort suggest that survival benefits increase with cumulative exposure to OAT.77
Evidence from previous studies suggests a strong association between OAT and lower risk of mortality when incarcerated, when released from incarceration while receiving OAT, and when receiving OAT after release from incarceration, with particularly lower risk of suicide and overdose mortality. Opioid agonist treatment was also found to be cost-saving as an intervention to reduce the risk of mortality after release from incarceration.78 Guidelines have been developed in the UK recommending and informing the use of OAT in carceral settings and after release79; international guidelines are also needed.
Future RCTs that withhold OAT are no longer ethical, and it is unlikely that future trials of OAT will be large enough to detect differences in mortality outcomes. The evidence base can be transformed and improved in 2 ways: (1) investing in research that tests how alternative ways of delivering OAT (and different medications) and adjunct interventions can improve retention, minimize elevated risk of mortality at initiation and maximize cost-effectiveness and (2) investing in data linkage studies that can create better-emulated trials and natural experiments of OAT delivery and combinations of interventions on mortality risk.
Limitations
This study had some limitations. The current evidence base in general was unrefined, lacking detail on clinical characteristics of patient history, intervention delivery, and consistent measures of confounders. For example, most cohorts did not specify whether treatment ceased because of dropout or completion. Those that did specify suggested that most patients dropped out of treatment as opposed to having a planned completion date.76,80 Morbidity was strongly associated with mortality risk and may also have been associated with retention.
There have been divergent findings according to which comorbidities are considered. One study found retention was higher among people with greater comorbidity (measured as the number of chronic diseases)76; another study suggested no association of HIV or HCV status with retention81; and an Australian study suggested that depression and other substance use disorders were associated with increased retention, whereas psychosis was associated with reduced retention (C. Bharat, personal communication, 2021). Moreover, cohort studies that have adjusted for comorbidity did not find changes in the estimated mortality risk by time during and out of OAT.
The evidence depends on observational studies that were subject to bias, confounding, and selection of participants. In most cohorts, there was little bias in measuring the outcome, but there were problems with missing data in some studies. However, we did find consistent data and little difference between adjusted and unadjusted estimates (Table 4). The evidence base could be substantially strengthened if future studies linked more detailed clinical information with mortality records so that more refined adjustments could be made for patterns and severity of opioid dependence, comorbidity, and environmental hazards on OAT retention and mortality risk.
Studies were largely limited to those who had received OAT for opioid dependence at some point. It is possible that mortality risk is higher for those who never receive OAT than it is for out-of-OAT periods among those who have some OAT experience, leading to an underestimate of the association between OAT and risk of mortality.
Despite the large numbers of people in the identified cohorts, for some causes of death, we had limited power, particularly when evaluating association during specific periods in and out of OAT. Similarly, there were insufficient studies to examine potential differences between buprenorphine and methadone by specific periods in and out of treatment.
Although associations were seen in this review, there have been too few studies of the influence of OAT during incarceration and after release. More studies using linked data that follow people through OAT during incarceration and after release, as conducted previously,18,71 are needed.
Conclusions
The results of this systematic review meta-analysis suggest that OAT is an important intervention for people with opioid dependence, with the capacity to reduce multiple causes of death. Despite this positive association, access to OAT remains limited in many settings, and in the US and globally, coverage for this type of treatment is low. Future work to increase access could have important population-level benefits.
Back to top
Article Information
Accepted for Publication: April 1, 2021.
Published Online: June 2, 2021. doi:10.1001/jamapsychiatry.2021.0976
Correction: This article was corrected on June 30, 2021, to fix an error in the Abstract; on March 16, 2022, to fix an incorrect rate ratio reported in the Abstract; and on July 19, 2023, to fix errors in the Results and Tables.
Corresponding Author: Thomas Santo Jr, MPH, National Drug and Alcohol Research Centre, UNSW Sydney, 22-32 King St, Randwick, NSW 2031, Australia (t.santo@unsw.edu.au).
Author Contributions: Mr Santo had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Santo, Clark, Hickman, Grebely, Tran, Farrell, Degenhardt.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Santo, Clark, Hickman, Chen, Farrell, Degenhardt.
Critical revision of the manuscript for important intellectual content: Santo, Clark, Hickman, Grebely, Campbell, Sordo, Tran, Bharat, Padmanathan, Cousins, Dupouy, Kelty, Muga, Nosyk, Min, Pavarin, Farrell, Degenhardt.
Statistical analysis: Santo, Clark, Grebely, Bharat, Cousins, Dupouy, Kelty, Nosyk, Min.
Obtained funding: Degenhardt.
Administrative, technical, or material support: Clark, Hickman, Sordo, Tran, Bharat, Nosyk, Degenhardt.
Supervision: Santo, Hickman, Campbell, Farrell, Degenhardt.
Other material support: Pavarin, Farrell.
Conflict of Interest Disclosures: Mr Santo reported receiving the Australian Government Research Training Program Fee Offset scholarship and Australian Federal Government Department of Health Grants National Centre Core Funding during the conduct of the study. Dr Hickman reported receiving grants from National Institute for Health Research & Medical Research Council for analysis of the data set included in this review during the conduct of the study and speaker honoraria from Merck Sharp & Dohme and Gilead in the past 3 years outside the submitted work. Dr Grebely reported receiving grants from AbbVie, Cepheid, Gilead Sciences, Hologic, Indivior, and Merck, and personal fees from AbbVie, Cepheid, Gilead Sciences, and Merck outside the submitted work. Dr Campbell reported receiving grants from Indivior and National Health and Medical Research Council Early Career Fellowship during the conduct of the study. Dr Bharat reported receiving the National Drug and Alcohol Research Centre and University of New South Wales Scientia PhD Scholarships outside the submitted work. Dr Dupouy reported being a member of a working group for and writing a recommendation on the proper use of prescribed opioid analgesics for the French High Authority of Health. Dr Farrell reported receiving grants from the Australian Federal Government Department of Health National Centre Core Funding, an united grant from Indivior to evaluate new opioid medications in Australia, and grants from Seqirus United to evaluate new opioid medications in Australia outside the submitted work. Dr Degenhardt reported receiving grants from National Health and Medical Research Council Fellowship, project funding and grants from the National Institutes of Health Project funding, grants from Indivior United to evaluate new opioid medications in Australia, and grants from Seqirus United to evaluate new opioid medications in Australia outside the submitted work. No other disclosures were reported.
Funding/Support: This work was supported in part by an Australian National Drug and Alcohol Research Centre scholarship (Mr Santo) and a University of New South Wales Sydney PhD scholarship (Mr Santo). The National Drug and Alcohol Research Centre is supported by funding from the Australian Government Department of Health under the Drug and Alcohol Program. This work was supported in part by grant APP1135991 from National Health and Medical Research Council Senior Principal Research Fellowship and grant R01DA1104470 from a National Institutes of Health National Institute on Drug Abuse grant (Dr Degenhardt); grant RFA-AI-18-026 from National Institutes of Health NIAID and grant APP1150078 from the Advancing the Health of People Who Use Drugs: Hepatitis C and Drug Dependence Program (Dr Degenhardt); support from National Institutes of Health Project Health Protection Research Unit in Behavioural Science and Evaluation at University of Bristol (Dr Hickman); support from the National Drug and Alcohol Research Centre and University of New South Wales Scientia PhD Scholarships (Ms Bharat); support from an National Health and Medical Research Council Emerging Leadership grant (Dr Kelty); support from National Health and Medical Research Council Investigator Award and the Kirby Institute, and grant 1176131 from National Health and Medical Research Council Investigator Grant (Dr Grebely); from grant AES PI19/00982 from the Acción Estratégica en Salud del Gobierno de España AES PI19/00982 (Dr Sordo); from the Michael Smith Foundation for Health Research Scholar (Dr Nosyk); from the Health Canada Substance Use and Addictions Program (Ms Min); by grant 1119992 from the National Health and Medical Research Council Early Career Fellowship and grant HRAPHR-2015-1088 from the Health Research Board, Ireland (Dr Campbell); by grant MR/N00616X/1 from Medical Research Council Addiction Research Clinical Training Programme (Ms Padmanathan); and by grants RD17/0017/0003 and PI20/0883 from the Ministry of Science and Innovation, Institute of Health Carlos III, Spain (Dr Sordo).
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The views expressed in this publication do not necessarily represent the position of the Australian government.
Additional Contributions: We thank (Kevin) Kun-Chia Chang, PhD, Charles Huang, PhD, Anders Ledberg, PhD, and Olga Morozova, PhD, for providing additional, unpublished data to inform our review. We thank Steven Batki, MD, Dana Bernson, MPH, John Devlin, PharmD, Javier Esteban, PhD, Elizabeth Evans, PhD, Linn Gjersing, PhD, Valerie Gruber, PhD, Sharon Hutchinson, PhD, Simeon Kimmel, MD, Marina Klein, MD, Barrott Lambdin, PhD, Barbara Lovrecic, MD, David Marsh, PhD, Michelle McKenzie, MPH, Tim Millar, PhD, Timothy Nielsen, MPH, Matthias Pierce, PhD, Stefanie Rezansoff, PhD, Josiah Rich, MD, Elana Rosenthal, MD, Angela Russolillo, MSc, Davida Schiff, MD, Andrew Stone, MD, Eric Strain, MD, Kinna Thakarar, DO, Helge Waal, MD, and George Woody, MD, for providing clarification of the data available for their cohorts. We thank Annabeth Simpson, MPH, for assistance through the screening and extraction stages. We thank Hayley Jones, PhD, for assistance with providing additional data for our review. No financial compensation was received for these contributions. Finally, we would like to thank Annick Bórquez, BSc, MSc, PhD, from University of California San Diego for identifying the errors in Table 3, which have been corrected.
References
Irvine MA, Kuo M, Buxton JA, et al. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic. Addiction. 2019;114(9):1602-1613. doi:10.1111/add.14664PubMedGoogle ScholarCrossref
Degenhardt L, Grebely J, Stone J, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560-1579. doi:10.1016/S0140-6736(19)32229-9 PubMedGoogle ScholarCrossref
Wen LS, Sadeghi NB. The opioid crisis and the 2020 US election: crossroads for a national epidemic. Lancet. 2020;396(10259):1316-1318. doi:10.1016/S0140-6736(20)32113-9 PubMedGoogle ScholarCrossref
Brignone E, George DR, Sinoway L, et al. Trends in the diagnosis of diseases of despair in the United States, 2009-2018: a retrospective cohort study. BMJ Open. 2020;10(10):e037679. doi:10.1136/bmjopen-2020-037679 PubMedGoogle ScholarCrossref
Larney S, Tran LT, Leung J, et al. All-cause and cause-specific mortality among people using extramedical opioids: a systematic review and meta-analysis. JAMA Psychiatry. 2020;77(5):493-502. doi:10.1001/jamapsychiatry.2019.4170 PubMedGoogle ScholarCrossref
World Health Organization. WHO Model list of essential medicines. Accessed February 15, 2020. https://www.who.int/groups/expert-committee-on-selection-and-use-of-essential-medicines/essential-medicines-lists
Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:10.1136/bmj.j1550 PubMedGoogle ScholarCrossref
Stevens GA, Alkema L, Black RE, et al; GATHER Working Group. Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement. Lancet. 2016;388(10062):e19-e23. doi:10.1016/S0140-6736(16)30388-9 PubMedGoogle ScholarCrossref
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264-269, W64. doi:10.7326/0003-4819-151-4-200908180-00135 PubMedGoogle ScholarCrossref
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008 PubMedGoogle ScholarCrossref
Examining the effect of opioid agonist treatment on all-cause and cause-specific mortality. PROSPERO identifier: CRD42020171949. Updated April 28, 2020. Accessed April 21, 2021. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=171949
Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919-i. doi:10.1136/bmj.i4919 PubMedGoogle ScholarCrossref
Sterne JA, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:I4898. doi:10.1136/bmj.l4898PubMed
Randall D, Roxburgh A, Gibson A, Degenhardt L. Mortality among people who use illicit drugs: a toolkit for classifying major causes of death. Accessed January 23, 2010. https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/Randall%20et%20al%20Classifying%20causes%20of%20death%202009%20corrected.pdf
StataCorp. Stata Statistical Software: Release 16. StataCorp, LLC; 2019.
Harris RJ, Deeks JJ, Altman DG, Bradburn MJ, Harbord RM, Sterne JA. Metan: fixed-and random-effects meta-analysis. SJ. 2008;8(1):3-28.
Harbord R, Higgins J. Metareg: Stata Module to Perform Meta-Analysis Regression. Boston College Department of Economics; 2009.
Larney S, Gisev N, Farrell M, et al. Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. BMJ Open. 2014;4(4):e004666. doi:10.1136/bmjopen-2013-004666 PubMedGoogle ScholarCrossref
Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O'Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33-40. doi:10.1016/j.drugalcdep.2014.05.011PubMedGoogle ScholarCrossref
Gruber VA, Delucchi KL, Kielstein A, Batki SL. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 2008;94(1-3):199-206. doi:10.1016/j.drugalcdep.2007.11.021PubMedGoogle ScholarCrossref
Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O'Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat. 2009;37(3):277-285. doi:10.1016/j.jsat.2009.03.002PubMedGoogle ScholarCrossref
Lee JD, Nunes EV Jr, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309-318. doi:10.1016/S0140-6736(17)32812-XPubMedGoogle ScholarCrossref
Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA. 2010;304(14):1576-1583. doi:10.1001/jama.2010.1427PubMedGoogle ScholarCrossref
Rich JD, McKenzie M, Larney S, et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015;386(9991):350-359. doi:10.1016/S0140-6736(14)62338-2PubMedCrossref
Strain E, Stitzer M, Liebson I, Bigelow G. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med. 1993;119(1):23-27. doi:10.7326/0003-4819-119-1-199307010-00004PubMedCrossref
Yancovitz SR, Des Jarlais DC, Peyser NP, et al. A randomized trial of an interim methadone maintenance clinic. Am J Public Health. 1991;81(9):1185-1191. doi:10.2105/ajph.81.9.1185PubMedCrossref
Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662-668. doi:10.1016/S0140-6736(03)12600-1PubMedCrossref
Krook AL, Brors O, Dahlberg J, et al. A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction. 2002;97(5):533-542. doi:10.1046/j.1360-0443.2002.00090.xPubMedCrossref
Schottenfeld RS, Chawarski MC, Mazlan M. Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9631):2192-2200. doi:10.1016/S0140-6736(08)60954-XPubMedCrossref
Tanum L, Solli KK, Latif ZE, et al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry. 2017;74(12):1197-1205. doi:10.1001/jamapsychiatry.2017.3206PubMedCrossref
Newman R, Whitehill W. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet. 1979;2(8141):485-488. doi:10.1016/s0140-6736(79)91550-2PubMedCrossref
Gunne LM, Grönbladh L. The Swedish methadone maintenance program: a controlled study. Drug Alcohol Depend. 1981;7(3):249-256. doi:10.1016/0376-8716(81)90096-xPubMedCrossref
Metzger DS, Donnell D, Celentano DD, et al. Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058. J Acquir Immune Defic Syndr. 2015;68(5):554-561. doi:10.1097/QAI.0000000000000510PubMedCrossref
Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment—a nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58-64. doi:10.1016/j.drugalcdep.2017.01.013 PubMedGoogle ScholarCrossref
Bakker A, Streel E. Benzodiazepine maintenance in opiate substitution treatment: good or bad? a retrospective primary care case-note review. J Psychopharmacol. 2017;31(1):62-66. doi:10.1177/0269881116675508 PubMedGoogle ScholarCrossref
Bukten A, Stavseth MR, Clasuen T. From restrictive to more liberal: variations in mortality among patients in opioid maintenance treatment over a 12-year period. BMC Health Serv Res. 2019;19(1):553. doi:10.1186/s12913-019-4382-9 PubMedGoogle ScholarCrossref
Buster MC, van Brussel GH, van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction. 2002;97(8):993-1001. doi:10.1046/j.1360-0443.2002.00179.x PubMedGoogle ScholarCrossref
Cousins G, Teljeur C, Motterlini N, McCowan C, Dimitrov BD, Fahey T. Risk of drug-related mortality during periods of transition in methadone maintenance treatment: a cohort study. J Subst Abuse Treat. 2011;41(3):252-260. doi:10.1016/j.jsat.2011.05.001 PubMedGoogle ScholarCrossref
Cousins G, Boland F, Courtney B, Barry J, Lyons S, Fahey T. Risk of mortality on and off methadone substitution treatment in primary care: a national cohort study. Addiction. 2016;111(1):73-82. doi:10.1111/add.13087 PubMedGoogle ScholarCrossref
Davoli M, Bargagli AM, Perucci CA, et al; VEdeTTE Study Group. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction. 2007;102(12):1954-1959. doi:10.1111/j.1360-0443.2007.02025.x PubMedGoogle ScholarCrossref
Dupouy J, Palmaro A, Fatséas M, et al. Mortality associated with time in and out of buprenorphine treatment in French office-based general practice: a 7-year cohort study. Ann Fam Med. 2017;15(4):355-358. doi:10.1370/afm.2098 PubMedGoogle ScholarCrossref
Durand L, O'Driscoll D, Boland F, et al. Do interruptions to the continuity of methadone maintenance treatment in specialist addiction settings increase the risk of drug-related poisoning deaths? a retrospective-cohort study. Addiction. 2020;115(10):1867-1877. doi:10.1111/add.15004PubMedCrossref
Fugelstad A, Stenbacka M, Leifman A, Nylander M, Thiblin I. Methadone maintenance treatment: the balance between life-saving treatment and fatal poisonings. Addiction. 2007;102(3):406-412. doi:10.1111/j.1360-0443.2006.01714.x PubMedGoogle ScholarCrossref
Grönbladh L, Ohlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82(3):223-227. doi:10.1111/j.1600-0447.1990.tb03057.x PubMedGoogle ScholarCrossref
Hickman M, Steer C, Tilling K, et al. The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom. Addiction. 2018;113(8):1461-1476. doi:10.1111/add.14188 PubMedGoogle ScholarCrossref
Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health. 2001;91(5):774-780. doi:10.2105/AJPH.91.5.774 PubMedGoogle ScholarCrossref
Marsden J, Stillwell G, Jones H, et al. Does exposure to opioid substitution treatment in prison reduce the risk of death after release? a national prospective observational study in England. Addiction. 2017;112(8):1408-1418. doi:10.1111/add.13779 PubMedGoogle ScholarCrossref
Morozova O, Dvoryak S, Altice FL. Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine. Int J Drug Policy. 2013;24(6):e91-e98. doi:10.1016/j.drugpo.2013.09.001 PubMedGoogle ScholarCrossref
Muga R, Rivas I, Faure E, et al. Sex-specific disease outcomes of HIV-positive and HIV-negative drug users admitted to an opioid substitution therapy program in Spain: a cohort study. BMC Infect Dis. 2014;14:504. doi:10.1186/1471-2334-14-504 PubMedGoogle ScholarCrossref
Pavarin RM, Fioritti A, Sanchini S. Mortality trends among heroin users treated between 1975 and 2013 in Northern Italy: results of a longitudinal study. J Subst Abuse Treat. 2017;77:166-173. doi:10.1016/j.jsat.2017.02.009 PubMedGoogle ScholarCrossref
Pierce M, Bird SM, Hickman M, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction. 2016;111(2):298-308. doi:10.1111/add.13193 PubMedGoogle ScholarCrossref
Scherbaum N, Specka M, Hauptmann G, Gastpar M. Does maintenance treatment reduce the mortality rate of opioid addicts?. Article written in German. Fortschr Neurol Psychiatr. 2002;70(9):455-461. doi:10.1055/s-2002-33758 PubMedGoogle ScholarCrossref
Weber R, Ledergerber B, Opravil M, Siegenthaler W, Lüthy R. Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. BMJ. 1990;301(6765):1362-1365. doi:10.1136/bmj.301.6765.1362 PubMedGoogle ScholarCrossref
Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend. 2009;105(1-2):9-15. doi:10.1016/j.drugalcdep.2009.05.021 PubMedGoogle ScholarCrossref
Digiusto E, Shakeshaft A, Ritter A, O’Brien S, Mattick RP; NEPOD Research Group. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004;99(4):450-460. doi:10.1111/j.1360-0443.2004.00654.x PubMedGoogle ScholarCrossref
Fellows-Smith J. Opioid-dependent error processing. J Opioid Manag. 2011;7(6):443-449.PubMedGoogle Scholar
Kelty E, Joyce D, Hulse G. A retrospective cohort study of mortality rates in patients with an opioid use disorder treated with implant naltrexone, oral methadone or sublingual buprenorphine. Am J Drug Alcohol Abuse. 2019;45(3):285-291. doi:10.1080/00952990.2018.1545131 PubMedGoogle ScholarCrossref
Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry. 2015;2(10):901-908. doi:10.1016/S2215-0366(15)00366-1 PubMedGoogle ScholarCrossref
Reece AS. Favorable mortality profile of naltrexone implants for opiate addiction. J Addict Dis. 2010;29(1):30-50. doi:10.1080/10550880903435988 PubMedGoogle ScholarCrossref
Bazazi AR. Characterizing and Responding to the Epidemics of HIV and Injection Drug Use in Malaysia. Dissertation. Yale University; 2018.
Chang KC, Lu TH, Lee KY, Hwang JS, Cheng CM, Wang JD. Estimation of life expectancy and the expected years of life lost among heroin users in the era of opioid substitution treatment (OST) in Taiwan. Drug Alcohol Depend. 2015;153:152-158. doi:10.1016/j.drugalcdep.2015.05.033 PubMedGoogle ScholarCrossref
Huang YF, Kuo HS, Lew-Ting CY, et al. Mortality among a cohort of drug users after their release from prison: an evaluation of the effectiveness of a harm reduction program in Taiwan. Addiction. 2011;106(8):1437-1445. doi:10.1111/j.1360-0443.2011.03443.x PubMedGoogle ScholarCrossref
Huang CL, Lee CW. Factors associated with mortality among heroin users after seeking treatment with methadone: a population-based cohort study in Taiwan. J Subst Abuse Treat. 2013;44(3):295-300. doi:10.1016/j.jsat.2012.08.003 PubMedGoogle ScholarCrossref
Liu E, Rou K, McGoogan JM, et al; China’s National Working Group on Methadone Maintenance Treatment. Factors associated with mortality of HIV-positive clients receiving methadone maintenance treatment in China. J Infect Dis. 2013;208(3):442-453. doi:10.1093/infdis/jit163 PubMedGoogle ScholarCrossref
Appel PW, Joseph H, Richman BL. Causes and rates of death among methadone maintenance patients before and after the onset of the HIV/AIDS epidemic. Mt Sinai J Med. 2000;67(5-6):444-451.PubMedGoogle Scholar
Evans E, Li L, Min J, et al. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015;110(6):996-1005. doi:10.1111/add.12863 PubMedGoogle ScholarCrossref
Gearing FR, Schweitzer MD. An epidemiologic evaluation of long-term methadone maintenance treatment for heroin addiction. Am J Epidemiol. 1974;100(2):101-112. doi:10.1093/oxfordjournals.aje.a112012 PubMedGoogle ScholarCrossref
Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169(3):137-145. doi:10.7326/M17-3107 PubMedGoogle ScholarCrossref
Pearce LA, Min JE, Piske M, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020;368:m772. doi:10.1136/bmj.m772 PubMedGoogle ScholarCrossref
Ledberg A. Mortality related to methadone maintenance treatment in Stockholm, Sweden, during 2006-2013. J Subst Abuse Treat. 2017;74:35-41. doi:10.1016/j.jsat.2016.12.005 PubMedGoogle ScholarCrossref
Degenhardt L, Larney S, Kimber J, et al. The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. Addiction. 2014;109(8):1306-1317. doi:10.1111/add.12536 PubMedGoogle ScholarCrossref
Lawlor DA, Davey Smith G, Ebrahim S. Commentary: the hormone replacement–coronary heart disease conundrum: is this the death of observational epidemiology? Int J Epidemiol. 2004;33(3):464-467. doi:10.1093/ije/dyh124 PubMedGoogle ScholarCrossref
Zhang FF, Barr SI, McNulty H, Li D, Blumberg JB. Health effects of vitamin and mineral supplements. BMJ. 2020;369:m2511. doi:10.1136/bmj.m2511 PubMedGoogle ScholarCrossref
Pintilie M. Competing Risks: A Practical Perspective: John Wiley & Sons; 2006. doi:10.1002/9780470870709
O’Connor AM, Cousins G, Durand L, Barry J, Boland F. Retention of patients in opioid substitution treatment: a systematic review. PLoS One. 2020;15(5):e0232086. doi:10.1371/journal.pone.0232086 PubMedGoogle ScholarCrossref
Nosyk B, MacNab YC, Sun H, et al. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol. 2009;170(6):783-792. doi:10.1093/aje/kwp186 PubMedGoogle ScholarCrossref
Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ. 2010;341:c3172. doi:10.1136/bmj.c3172 PubMedGoogle ScholarCrossref
Gisev N, Shanahan M, Weatherburn DJ, et al. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. Addiction. 2015;110(12):1975-1984. doi:10.1111/add.13073 PubMedGoogle ScholarCrossref
Department of Health. Drug misuse and dependence. Accessed April 15, 2020. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/673978/clinical_guidelines_2017.pdf
Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ. 2010;341(7779):c5475. doi:10.1136/bmj.c5475 PubMedGoogle ScholarCrossref
Zhang L, Zou X, Zhang D, Li X, Zhao P, Ling L. Investigation of repeat client drop-out and re-enrolment cycles in fourteen methadone maintenance treatment clinics in Guangdong, China. PLoS One. 2015;10(10):e0139942. doi:10.1371/journal.pone.0139942PubMedCrossref
X
.
Access your subscriptions
Add or change institution
Free access to newly published articles
To register for email alerts, access free PDF, and more
Purchase access
Get full journal access for 1 year
Get unlimited access and a printable PDF ($40.00)—
Sign in or create a free account
Rent this article from DeepDyve
Access your subscriptions
Add or change institution
Free access to newly published articles
To register for email alerts, access free PDF, and more
Purchase access
Get full journal access for 1 year
Get unlimited access and a printable PDF ($40.00)—
Sign in or create a free account
Rent this article from DeepDyve
Sign in to access free PDF
Add or change institution
Free access to newly published articles
To register for email alerts, access free PDF, and more
Save your search
Free access to newly published articles
To register for email alerts, access free PDF, and more
Purchase access
Customize your interests
Free access to newly published articles
To register for email alerts, access free PDF, and more
Create a personal account or sign in to:
- Register for email alerts with links to free full-text articles
- Access PDFs of free articles
- Manage your interests
- Save searches and receive search alerts
Make a comment
Free access to newly published articles
To register for email alerts, access free PDF, and more
Create a personal account or sign in to:
- Register for email alerts with links to free full-text articles
- Access PDFs of free articles
- Manage your interests
- Save searches and receive search alerts